CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry

Launched by COREVITAS · Feb 16, 2023

Keywords

ClinConnect Summary

The CorEvitas Alopecia Areata Safety and Effectiveness Registry is a clinical study aimed at understanding how safe and effective different treatments are for alopecia areata, a condition that causes hair loss. This study will involve around 5,000 people across 100 dermatology clinics in North America. Participants will be adults aged 18 and older who have been diagnosed with alopecia areata by a dermatologist and are currently starting or have been prescribed a medication for their condition.

If you decide to participate, you can expect to share some personal information and details about your health and treatment. This study is observational, meaning that researchers will track how well the treatments work and any side effects, without changing how you are treated. Importantly, if you are already taking part in a different type of clinical trial that involves random assignments of medications, you won't be able to join this study. However, if you are in an observational study, you can still participate. This registry aims to gather valuable information that can help improve care for people with alopecia areata in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * A subject must meet all the following criteria to participate in the registry:
• • 1. Has been diagnosed with alopecia areata by a dermatologist or a qualified dermatology practitioner.
• • 2. Is at least 18 years of age or older.
• • 3. Is willing to provide Personal Information.
• • 4. Is prescribed or starting an Enrollment Eligible Medication at the time of enrollment.
• Exclusion Criteria:
• * Any of the following would exclude the subject from participating in the registry:
• 1. Is participating or planning to participate in a double-blind randomized trial for an AA drug. Note:
• • Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed.